Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.
Contact | 
Explore Technologies



New Light Control Mechanism (NpHR) That Inhibits Neural Activity


Stanford Reference:

06-398


Abstract


The inventors have identified and developed an archaeal light-driven chloride pump (NpHR) from Natronomonas pharaonis for temporally precise optical inhibition of neural activity. NpHR allows either knockout of single action potentials, or sustained blockade of spiking. NpHR is compatible with ChR2, the previous optical excitation technology from their laboratory (Stanford Docket S05-170), in that the two opposing probes operate at similar light powers but with well-separated action spectra. NpHR, like ChR2, functions in mammals without exogenous cofactors, and the two probes can be integrated with calcium imaging in mammalian brain tissue for bidirectional optical modulation and readout of neural activity. Likewise, NpHR and ChR2 can be targeted together to Caenorhabditis elegans muscle and cholinergic motor neurons to control locomotion bidirectionally. NpHR and ChR2 form a complete system for multimodal, high-speed, genetically targeted, all-optical interrogation of living neural circuits.

Additional optical control of neural circuitry using NpHR is described in Stanford Docket S06-398A.

Stage of Research
The inventors have developed eNpHR (enhanced NpHR), an improved version of NpHR for safe expression at high levels under strong promoters and with augmented inhibitory function in vitro and in vivo.

Applications


  • Optical inhibition of neural activity for therapeutic and research purposes

Advantages


  • When combined with the engineered Channelrhodopsin ChR2, the NpHR/ChR2 system enables rapid bidirectional control of neurons on the timescale of milliseconds, thus enabling emulation or alteration of the neural code. These fast genetically based, neural-spike-controlling technologies powerfully augment existing tools for interrogating neural systems.

Publications



Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 10/8/2020 12:00
 

Licensing Contact


Evan Elder, Associate Director, Licensing and Strategic Alliances, Physica
650-725-9558 (Mobile)
Request Info

92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)
95-006 G-Protein-Linked Receptor-Transfected Lymphoid Cell as Tools for Drug Discovery and for Cellular Therapeutics

more technologies »

Related Keywords


ion channels   epilepsy   MD: neurology   MD: neurology: neuromodulation   neuronal circuits   LS: General Therapeutic: Psychiatric Diseases   neuroscience   parkinson's disease   screening   seizure   LS: general therapeutic: CNS (neurology / central nervous system)   Coulter   06-398   therapeutic